Pogacar vs Vingegaard? Alcaraz vs Sinner? Tottenham vs Arsenal? Giants vs Dodgers? Nemesis vs motivation?

I think this is a great idea, might be tricky to operationalise. The current system is breaking if not already broken. Incentivises research fraud. Will prevent people seeing the wood because of all the dodgy trees. #LessIsMore

This makes me sad (not altogether sure why), but I would like thank #DanielLevy for his hard work over last 25 yrs. The Stadium, European Glory Nights, Great teams, superstar players! 😍 There were some lows I’m sure but I don’t remember those. #COYS

Phenomenal result! FIRST positive 52 week study of inhaled therapy in #IPF. Benefits were independent of background therapy! 🤩 Along with Nerandomilast this shows importance of cAMP/PDE4 pathways in fibrosis & opens door 4 other therapies targeting these pathways! #FutureLooksBright #CureIPF

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁 Positive trial 🗞️ Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD @ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social www.theglobeandmail.com/investing/ma...

I think there is no clinical need to update the classification, and I just can’t wait for the next update! 🥱

I’ve just been struck by how structurally (if not functionally) similar broccoli 🥦 is to the lungs 🫁! 😍🤣

This isn’t about Republicans or Democrats or anything to do with politics This is about men exploiting and committing sexual violence against women and girls THIS is the issue to bring to the forefront address

People’s brains aged faster during the COVID pandemic — even the uninfected @nature.com www.nature.com/articles/d41... @natcomms.nature.com @alirezamnk.bsky.social @spmic-uon.bsky.social @ipfdoc.bsky.social www.nature.com/articles/s41...

1. Kevin Gross and I just posted a new science-of-science preprint. This one explores the looming peer review crisis. As many of you know, it's becoming significantly more difficult for journal editors to find scholars willing to serve as peer reviewers for submitted manuscripts.

Incidence, Prevalence & Mortality of ILDs in Alberta, Canada Derived, tested case definitions performed well, created a dataset of ILD. Incidence was stable, prevalence increased, mortality decreased for ILD & IPF sub-group @kerrijohannson.bsky.social @agrantorser.bsky.social tinyurl.com/5n7x5w2h

🎙️ Just published a #NEW episode of Out of the Blue: An AJRCCM Podcast: Approach to the Evaluation and Management of Interstitial Lung Abnormalities @atscommunity.bsky.social #medsky Have a listen: outoftheblue.transistor.fm

If only all bridges were like this! #HammersmithBridge #ILoveLondon

Great article from @theguardian.com which nicely summarises a real problem. As I’m fond of saying ‘if you are looking for a needle in a haystack, stop adding more hay!’ Thanks for sharing @kerrijohannson.bsky.social @bmj.com

Tips for academic sustainability: Only review for journals you know Do not submit to predatory journals Do NOT contribute to this crap Stop thinking about 'getting papers' and think about 'advancing your field' - this needs to change for promotion and merit www.theguardian.com/science/2025...

How many people ask permission from proposed reviewer when they ‘recommend’ a reviewer for submitted publication? Fairly standard when requesting professional reference and might reduced the number of declined reviews from ‘recommended reviewers’? #AnswersOnAPostcard

NEWSFLASH, any reviewer for BMJOpenRespRes gets a 25% discount on the APC for manuscripts submitted to BMJOpenRespRes within 12 months. There maybe further positive moves in future #SmallSteps. #GettingThere 🙏🙏

Wow! 🤩 Some really important messages in here! The burden of ILD is higher than thought AND rising. Burden in rural communities higher than cities! 🤔?🌾🚜🐤 Mortality 📉 suggests Dx and Mx improving 🥳 Kudos to @kerrijohannson.bsky.social & team!

Important! A population based study of trends in incidence, prevalence, mortality of ILD over 10 yrs. Good news: Mortality ⬇️. Expected news: Incidence unchanged, Prevalence ⬆️ Important News: there are a lot of ILD patients 👏🏼 Drs Johannson, Fisher & team!!! www.atsjournals.org/doi/full/10....

Kudos to the amazing team from University of Calgary Centre for Health Informatics, support from the AB ILD UHF grant (without whom this would not be possible), and collaborators including @agrantorser.bsky.social Dr. Jolene Fisher & @annalsats.bsky.social for appreciating the value of this work 💪🫁😊

Incidence, Prevalence, and Mortality of Interstitial Lung Diseases in Alberta, Canada: A Population-based Study www.atsjournals.org/doi/suppl/10... 🧵👇 📣 TL:DR Incidence stable, prevalence rising, improved survival for ILD & IPF over 10 years. Numbers much higher than prior reports for ILD & IPF.

Peer review as it’s currently done is baloney and often meaningless. Keep in mind I don’t publish in Science or Nature. The whole process of knowledge dissemination needs an overhaul and redefining of metrics.

I just stepped down from editorial board of a Nature subsidiary journal. Sending 300 invites to get 2 accept is soul-destroying. And I wasn’t paid as an editor for handling 10 papers at a time never mind the reviewers! #pay4peerreview

🤣🤣🤣🤣🤣🤣

It’s a practical question not a philosophical one. If the choice is wait many months while AEs try & fail to get reviews or get your manuscript back for resubmission elsewhere which is an authors preference?

We can’t desk accept because by definition it’s not been peer reviewed. Therefore, the journal would no longer ‘a peer reviewed journal’ which is criterion for most academic promotions, grants etc. In which case people might as ell deposit on their institutional website only.

Question for the #Medicine #Science community about peer review in the context of time to decision. Would people prefer a limit on review declines before an automatic desk reject? Eg 10 reviewers decline manuscripts auto rejected, or keep on trying? Like 4 auto reject Repost 4 keep on trying

Hopefully other journals will up their game soon 🙏Maybe AI will help? @bmj.com

Agee. Quality not easily measured by IF but should be the driving factor with good & fair service provided to authors. There is a lot of work to be done to reach this standard! 😔 #WillKeepTrying

I’ll be perfectly honest. I couldn’t care less about IF. All I want is for my work to handled appropriately, in unbiased fashion, and published in journals with analogous quality work. This is what all these journals should be striving for, and frankly there’s a lot of work to be done for most.

It that JIF time of year again and here they are. Some surprising movement which leaves me & I’m sure other wondering a) what does it mean & b) will journals adjust strategy or process as a result! No change at the top: @lancetrespirmed.bsky.social 32.1 However coming in at number 2 🥁🥁

Also: What IS fHP without an antigen?? Stay tuned as we aim to find out ... 😊🦜🫁 Kudos to CARE-PF team, especially Dr. Chris Ryerson (not on bsky yet ...) @gilliangoobie.bsky.social @agrantorser.bsky.social @veronicasam940.bsky.social

"Typical for fHP" on HRCT might not be fHP at all! Using a diagnostic term for HRCT pattern is misleading and inconsistent with what we do with UIP or NSIP patterns A descriptive term would be better for a radiologic pattern (i.e. bronchiolocentric interstitial pneumonia) 🩻

Just out in @atsblueeditor.bsky.social from 🇨🇦 CARE-PF🫁 Did you ever wonder what a "typical for fibrotic HP" HRCT pattern really means? We aimed to find out ... 🧐 www.atsjournals.org/doi/10.1164/...

@ipfdoc.bsky.social, @kottond.bsky.social, @francypolverino.bsky.social @msbr89.bsky.social ‪@varelaslab.bsky.social @lisyvila.bsky.social @carolavoss.bsky.social ‬ please share to let your followers know :)

Will REMAP-ILD contribute to understanding and improving outcomes for Multiple Long Term Conditions? I think so! @nihr.bsky.social @ukri.org @kerrijohannson.bsky.social @kaminskimed.bsky.social @actionpfcharity.bsky.social

I tell ya Tammy Bruce is gonna be a 🌟! Her presser was quite the event especially from 6-10 minutes. 😅😅 #TammyIsAwesome www.youtube.com/live/oy2JOqH...

"With Sadness and Resolve: Why I Resigned as Chief Medical Officer of an NIH Institute and What Comes Next" Dr. Josh Fessel MD PhD ATSF 1. Limit the damage 2. Tell the stories of science & scientists 3. Protect the next generation O/A @annalsats.bsky.social 🫁 www.atsjournals.org/doi/abs/10.1...

Proud to have have topped the poll in the council election. I hope to be of use, and look forward to working with Mumtaz Patel Hilary Williams and the rest of the @rcphysicians.bsky.social team. Thanks @drasifqasim.bsky.social @respirologist.bsky.social @martinmckee.bsky.social for nominating me.

#ILDSky #CureIPF #CurePF Nintedanib for SSc-ILD at Scleroderma centres in the US. Not one 🫁 MD on this paper 👀 Are Rheumatologists treating/managing ILD at your centres? @jskim8223.bsky.social @ipfdoc.bsky.social @tkulkarni.bsky.social @istamina.bsky.social

The Blue Journal thanks Kerri A. Johannson, MD, MPH, FRCPC, ATSF, for her contribution to the April issue Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease kerrijohannson.bsky.social www.atsjournals.org/doi/full/10....

Powerful report in @theguardian.com about the harms of abortion bans outside obstetrics by @skirchy.bsky.social regarding new scientific study by @hauschildt.bsky.social in @accpchest.bsky.social www.theguardian.com/us-news/2025...

Great to host Vidya Navaratnam MTWCentre. Her seminar places supportive care at centre stage! Raises really important questions about care at end of life & impact on survival and hospitalisations. Needs urgent further study! @kerrijohannson.bsky.social @kaminskimed.bsky.social

Excited to share Ruqian has developed a package for this transcript based niche analysis. Check out the preprint and the package! This is a flexible approach and we're working on extending this for other spatial analyses! @davisjmcc.bsky.social www.biorxiv.org/content/10.1...

Elon Musk said #Canada is not a real country. We say X is not a real social media platform any more. You can follow the @cmadocs.bsky.social here, on other platforms and, best of all, through our own website - www.cma.ca/latest-stori.... #ElbowsUp 🟥🍁🟥

Scammers playing on my ego! 🤣🤣 Just as well awards are not my motivation for doing science and medicine! #CureIPF

Over yrs involved in #MedPublishing I have spent much time a) trying to obtain peer review & b) answering author complaints about delays due to lack of peer review. This invirtuous circle is getting worse. Should we a) dispense with peer review altogether or b) outsource to AI or c) something else?

Found it strangely reassuring as I reflected on my recent exploration of Istanbul, London & Siena. The history & complexity of these wonderful places reassures me Europe will withstand current challenges & emerge stronger, more vibrant than ever. I hope random younger countries fare so well. 🙏🙏